Quantitative rapid free light chain test registered in Brazil

eTradeWire News/10522121
Abingdon Health is pleased to announce Seralite® – FLC Serum, which can be used to diagnose and manage patients with multiple myeloma, has been granted registration by the Brazilian Health Regulatory Agency (ANVISA)

YORK, England - May 20, 2019 - eTradeWire -- Seralite® – FLC is a rapid lateral flow test for the quantitative measurement of kappa (K) and lambda (λ) immunoglobulin free light chains (FLCs) in serum. The format of this rapid test enables a free light chain service to be offered in all clinical laboratories. This enables the provision of FLC results in ~10 minutes rather than days or weeks. With this simple to use, compact, rapid test, clinicians are able to monitor patients in "real time" supporting faster decision making.

More on eTradeWire News
This is a key registration for Seralite® – FLC and underpins the regional strategy for Latin America. In conjunction with Seralite® – FLC Serum, Seralite® – FLC LFD Controls and the ADxLR5® Reader System have also been granted registration. Latin America has a population of 606 million people and with a market size of more than US$2.4bn is a key emerging IVD market.

With this registration in Brazil, Seralite® – FLC is now available in 73 countries worldwide. Seralite® – FLC is distributed globally (with the exception of Benelux), by Sebia, the world leader in medical diagnostics for electrophoresis.

To learn more about Seralite® – FLC please visit https://www.abingdonhealth.com/medical-diagnostics/seralite/.

Source: Abingdon Health
stats
Filed Under: Health

Show All News | Report Violation

0 Comments